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ABSTRACT
Background: Intravesical Bacille Calmette-Guérin (BCG) immunotherapy 
has been used for several decades as a prophylactic approach against recurrence of superfi-
cial bladder cancer. However, its effectiveness has been both variable and unpredictable. 
Typically, cancer BCG-immunotherapy aims to redirect or modulate both innate and adap-
tive immune responses. The consequences of gene polymorphisms in several key immuno-
regulatory molecules on the heterogeneity of the response to BCG-immunotherapy 
have been investigated.
Objective: The aim of this study was to evaluate the association of toll-like 
receptor (TLR) 2 polymorphisms (arginine to glutamine substitution at position 753 
[Arg753Gln] and arginine to tryptophan substitution at position 677 [Arg677Trp]) 
and the outcome of BCG-immunotherapy.
Methods: This prospective study was conducted during a 3-year period 
from June 2006 to July 2009. Consecutive patients were recruited during a 1-year 
period and followed for 2 years at the Department of Urology, Charles Nicolle 
Hospital, Tunis, Tunisia. Patients with superficial bladder tumors at stage Ta 
(noninvasive papillary carcinoma) or T1 (where the tumor has grown from the layer 
of cells lining the bladder into the connective tissue below but has not grown into 
the muscle layer of the bladder) of any grade were eligible; carcinoma in situ cases 
were excluded. The TLR2 Arg753Gln and Arg677Trp polymorphisms were studied 
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in peripheral blood DNA from patients treated with BCG-immunotherapy after 
transurethral resection.
Results: A total of 112 consecutive patients were enrolled (101 men and 
11 women; mean age, 63.9 years [range, 25–85 years]) and completed the 2-year follow- 
up. Polymerase chain reaction amplification followed by direct sequencing of the region 
containing the TLR2 single-nucleotide polymorphism (SNP) of interest did not detect 
Arg753Gln or Arg677Trp in any of the study participants belonging to either of 
2 groups: responders (n = 67) and nonresponders (n = 45) to BCG-immunotherapy.
Conclusions: No patients included in the study were found to have the 
2 known TLR2 nonsynonymous SNPs, and the relative importance of these polymor-
phisms could not be definitely determined. However, a significant proportion of pa-
tients without these polymorphisms responded to BCG-immunotherapy, suggesting 
that these genetic variants are not critical in the effectiveness of this approach for 
preventing recurrence of the tumor. (Curr Ther Res Clin Exp. 2010;71:398–407) © 
2010 Elsevier HS Journals, Inc.
Key words: genetic polymorphism, BCG-immunotherapy, TLR2, bladder, 
cancer.
INTRODUCTION
Toll-like receptors (TLRs) are primary transmembrane proteins of immune cells that 
play a critical role in innate and adaptive immunity. TLRs have been determined as 
playing a central role in the detection of pathogen-associated molecular patterns and 
to mediate cellular responses.1 Currently, 13 TLRs (TLR1–TLR13) have been identi-
fied in mammalian species, including 11 in humans.2 TLR2 has been found to be 
important in the control of mycobacterial infections.3 Mycobacterial agonists of TLR2 
include lipoproteins and glycolipids.
Intravesical Mycobacterium bovis Bacille Calmette-Guérin (BCG) treatment is effec-
tive against carcinoma in situ and is used as a prophylaxis against recurrence of super-
ficial bladder cancer.4 However, its outcome is unpredictable. Understanding the 
mechanisms that underlie its success and eventually identifying genetic markers that 
might help predict the response of patients with bladder cancer may be critical to 
better adapt the present BCG-immunotherapy protocols. Indeed, the association be-
tween gene polymorphisms in several key immunoregulatory molecules (eg, natural 
resistance-associated macrophage protein 1, cytokines and their receptors) and the 
response to BCG-immunotherapy have been investigated.5,6 Interestingly, several in-
vestigators have found that single-nucleotide polymorphisms (SNPs) in human TLR2, 
a pattern recognition receptor involved in mycobacteria-mediated intracellular signal-
ing,7 might increase the risk for mycobacterial infections like tuberculosis8 and lep-
rosy.9,10 Indeed, the polymorphism of TLR2 (substitution of an arginine to a trypto-
phan at position 677 [Arg677Trp]) was found, in initial studies, to be associated with 
lepromatous leprosy in Korean patients11 and with tuberculosis in Tunisian patients.12 
Another polymorphism of TLR2 (arginine to glutamine substitution at position 753 
[Arg753Gln]) was found to be associated with tuberculosis in Turkish patients.13
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While the overall consequences of BCG binding to the uroepithelial surface are 
poorly understood,4 it is clear that BCG interaction with uroepithelial cells is ac-
tive rather than passive. BCG adherence induces the expression of genes by blad-
der tumor cells, such as interleukin (IL)-6 and tumor necrosis factor α,14 as well 
as IL-8.15 Interestingly, BCG adherence stimulates tumor cell expression of IL-6 
through an immediate-early pathway requiring the signal transducers nuclear 
factor kappa-light-chain-enhancer of activated B cells and activator protein 1.16 
This might occur through adhesion-mediated signaling by receptor interaction or 
through an attachment-facilitated presentation of conserved microbial patterns 
to TLRs on uroepithelial cells.15 The present study focused on the detection of 
nonsynonymous SNPs in the TLR2 coding region and their possible association 
with BCG immunotherapy response in Tunisian patients with superficial bladder 
cancer.
PATIENTS AND METHODS
Patients
This prospective study was conducted during a 3-year period from June 2006 to 
July 2009. Consecutive patients, recruited during a 1-year period, underwent com-
plete transurethral resection (TUR) of the bladder tumor and were followed for 
2 years at the Department of Urology, Charles Nicolle Hospital, Tunis, Tunisia. No 
patients were excluded. Patients were eligible for enrollment after histologic confir-
mation of superficial bladder cancer and treatment by TUR followed by a complete 
BCG-immunotherapy instillation protocol. Patients with tumors at stage Ta (con-
fined to the urothelium) or T1 (extending to the lamina propria but superficial to 
the muscularis propria) of any grade were eligible.17 Patients were treated by the 
following adopted protocol: 6 weekly intravesical instillations of BCG (BCG Pas-
teur strain, 50 mg in 50 mL saline) and then by 12 additional monthly instillations. 
Patients were followed every 3 months for 24 months; at each follow-up, urine cy-
tology and cystoscopy status were checked. A cystoscopic biopsy was taken from any 
visible lesion to confirm histology. Patients’ follow-up was calculated as the number 
of months from the date of surgical procedure and diagnosis to the date of the last 
control cystoscopy. Responders to BCG-immunotherapy were defined as patients who 
did not have evidence of recurrence of their tumor during the 24-month follow-up, 
while nonresponders did have evidence of recurrence. The end point for follow-up was 
either development of recurrence or the termination date of the study. The statisti-
cal analysis was conducted by correlating the potential genetic polymorphisms and 
recurrence of the tumor in order to identify a predictive recurrence-free survival 
factor. Written informed consent to participate in the investigation was obtained 
from all subjects. The Tunisian population is in the Hardy-Weinberg equilibrium. 
Indeed, both allele and genotype frequencies remain constant as demonstrated 
through the analysis of 10 short tandem repeat markers validated for use in Tunisian 
national forensic biology (D. Fathallah, oral communication, April 1998). During 
initial diagnosis, peripheral blood samples were collected from all patients into 
EDTA tubes for DNA extraction.
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Study Design
Genomic DNA was extracted from 5 mL of EDTA-anticoagulated blood using a 
phenol-chloroform procedure. To determine the TLR2 genotype, the genomic DNA 
was amplified using forward (5'-GTGTCGGAATGTCACAGGAC-3') and reverse 
(5'-CCTCAAATGACGGTACATCCA-3') primers that span the region containing the 
Arg677Trp and Arg753Gln polymorphisms. Polymerase chain reaction (PCR) was 
performed (Model 9700 Gene Amp PCR system, Applied Biosystems, Foster City, 
California) in a total volume of 50 μl consisting of 5 μL of 10 μL reaction buffer (20 
mM Tris hydrogen chloride [pH 8.8], 50 mM potassium chloride, 15 mM magnesium 
chloride), 0.5 μL of deoxynucleoside triphosphate mix (25-mM solution), 5 U of DNA 
polymerase (AmpliTaq, Amersham Biosciences, Little Chalfont, United Kingdom), 
25 pmoL of each primer, and 5 μL of genomic DNA (100 ng). PCR was performed 
under the following conditions: 5 minutes of initial denaturation at 95°C, 30 cycles 
of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 1 minute, followed by one 
elongation step at 72°C for 1 minute. PCR products were subjected to electrophoresis 
in a 1% agarose gel, stained with ethidium bromide, and visualized under ultraviolet 
light. All nucleotide sequences were obtained using a cycle sequencing kit (BigDye 
Terminator Kit, Applied Biosystems, Little Chalfont, United Kingdom) and an auto-
mated sequencer (Model 3100, Applied Biosystems, United Kingdom) with 1 μL of 
the reverse primer (5'-CCTCAAATGACGGTACATCCA-3'). All quality controls 
for PCR and direct sequencing were rigorously followed. Sequence alignment and 
SNP search were conducted using BioEdit software (Centre National de Génotypage, 
Evry, France).
RESULTS
A total of 112 patients were enrolled including 101 male and 11 female with a sex ratio 
of 9.18 (mean age, 63.9 years [range, 25–85 years]). All patients were Tunisian. All 
enrolled patients survived to the end of the 24-month follow-up and were included in 
the genetic study. BCG-immunotherapy was conducted according to the International 
Protocol for administration. Furthermore, and according to the World Health Organiza-
tion classification18 among nonresponders, the tumor grading was established as low ma-
lignant potential papillary carcinoma (G1) in 15 patients, intermediate (G2) in 21 pa-
tients, and high (G3) in 9 patients; while among responders, 29, 28, and 10 patients 
were classified as G1, G2, and G3, respectively. The cohort of patients included 67 re-
sponders (59.8%) and 45 nonresponders (40.2%) to BGC-immunotherapy.
PCR amplification followed by direct sequencing of the region containing the 
TLR2 SNPs of interest detected neither C to T mutation at position 2029 that results 
in Arg677Trp (Figure 1), nor G to A mutation at 2251 that results in Arg753Gln 
(Figure 2) in any of the study participants.
DISCUSSION
Two SNPs in the intracellular toll/IL-1 receptor domain of TLR2 have been described 
that influence cell-type specific activation, nature, and signal transduction pathways 
of the immune response.9,19 These polymorphisms, Arg677Trp and Arg753Gln, have 
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been reported in some studies to be associated in humans with susceptibility to tuber-
culosis due to Mycobacterium tuberculosis, as well as to susceptibility to leprosy due to 
Mycobacterium leprae.11–13 In this study, we did investigate the presence of these poly-
morphisms and their eventual association with the favorable/unfavorable outcome of 
M bovis–BCG-immunotherapy when used as a prophylactic approach against the re-
currence of superficial bladder cancer patients. BCG interaction with uroepithelial 
and, eventually, innate immunity cells is thought to mediate an inflammatory im-
mune response that is beneficial against the recurrence of the disease in a significant 
score of patients with superficial bladder cancer.15 TLR2 as a major pattern recog- 
nition receptor involved in mycobacterium-mediated intracellular signaling may be 
critical in this regard and its potential polymorphisms could be predictive factors for 
the outcome of BCG-immunotherapy.
T TG T C TA T TA C T T C C G C G C T TA
170 180
Figure 1.  Sequencing results of arginine to tryptophan substitution at position 677 in 
toll-like receptor 2 genomic DNA. Homozygous C/C (wild type/wild type) 
genotype.
A TG C C GC C TT A G A A G CA
410 420
T
Figure 2.  Sequencing results of arginine to glutamine substitution at position 753 in toll-
like receptor 2 genomic DNA. Homozygous G/G (wild type/wild type) 
genotype.
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The present study is, to the best of our knowledge, the first to evaluate such a 
hypothesis. It was designed to recruit all consecutive patients attending a single medi-
cal center. All patients approached for enrollment were eligible according to the inclu-
sion criteria. None among them was excluded and all of them survived the 24-month 
follow-up. The number of patients enrolled was limited to those consecutively identified 
during a 1-year period. At the end of the 24-month follow-up, they were subdivided 
into 2 groups of responders/nonresponders to BCG-immunotherapy and recruited for 
genetic study.
The present results found that the SNP Arg677Trp, which was expected to give rise 
to an anergic phenotype for mycobacterial infections, was not found in these Tunisian 
patients, regardless of their BCG immunotherapy response status. Indeed, 224 alleles in 
this study were observed and showed no evidence for the presence of this TLR2 SNP. 
Interestingly, this is consistent at least in regard to Arg677Trp with the results of 
recent studies that identified no individuals carrying this polymorphism in popula-
tions including Indians,20 Koreans,11 whites,21,22 and Chinese.11 Indeed, Malhotra et 
al20 revisited the association between this polymorphism and leprosy, and demon-
strated that the TLR2 Arg677Trp is not a real polymorphism. They found that this 
variant is present in the duplicated region of exon 3 situated ~23 kb upstream of the 
TLR2 gene with 93% homology with the authentic exon 3 of TLR2. In consequence, 
the use of primers designed to exclusively amplify the TLR2 authentic sequence is 
critical to avoid any misinterpretation of the results. In the present study, we used 
such primers in contrast to the first study of tuberculosis in Tunisian patients where 
primers also amplifying the pseudogene had been used.12
The Arg753Gln SNP has been found to be present in 9% to 10% of whites includ-
ing German,23 Brazilian,24 Italian,25 and Belgian populations26 (Table), and has been 
found to be associated with tuberculosis, asthma, and septic shock.13,20,27 Mutlubas et 
al28 found an association between chronic allograft nephropathy and this poly- 
morphism. In our study, 224 alleles in total have been studied and showed no evidence 
for the presence of this TLR2 SNP. Along with our study, other studies have found 
that this polymorphism was absent among Korean and Chinese populations.29–31
This study did have important limitations. No patients with the polymorphism 
were identified, making it impossible to evaluate the relative importance of the poly-
morphism for BCG efficacy. However, the fact that there were responders and nonre-
sponders in the cohort suggests that the polymorphism is not critical for BCG efficacy. 
Further studies using larger cohorts are needed to better assess the role of these poly-
morphisms, if any.
Although BCG-immunotherapy after initial TUR in patients with superficial 
bladder cancer is more effective than chemotherapy, some patients are at greater risk 
for recurrence and progression than others. Genetic factors may contribute to this 
heterogeneous and, to date, unpredictable response.
CONCLUSIONS
In this prospective study, none of these Tunisian patients with superficial bladder 
cancer were found to have either of the 2 known TLR2 nonsynonymous SNPs and the 
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relative importance of these polymorphisms could not be definitely determined. However, 
67 of 112 individuals (59.8%) without these polymorphisms responded to BCG in the 
present study.
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